FDA approves Alvotech’s new SIMLANDI process, doubling output per batch and signaling manufacturing progress

What happened

Alvotech announced FDA approval for a new manufacturing process for SIMLANDI (AVT02), its adalimumab biosimilar, which more than doubles output per batch. The company states the enhanced process increases productivity and frees capacity to support growing demand across its biosimilar portfolio. This approval is a positive signal that the FDA is engaging constructively on manufacturing changes at the Reykjavik facility, which has been under scrutiny following a November 2025 CRL for AVT05 and prior manufacturing deficiencies. However, the approval is specific to SIMLANDI’s already-marketed process and does not directly resolve the outstanding AVT05 issues or the broader quality-system concerns that have pressured the stock. Investors should view this as an incremental operational improvement that may support margins and capacity utilization, but the primary risk remains the successful remediation and approval timeline for AVT05 and other pipeline assets.

Implication

If the improved process can be validated across other products and the FDA’s engagement signals a thaw in regulatory relations, Alvotech’s single-site manufacturing could become more efficient, supporting the bull case. However, until AVT05 remediation is conclusively demonstrated and the company shows sustained product-driven cash flow, the balance sheet and execution risks warrant continued caution. The approval does not change the fundamental risk profile but suggests incremental progress.

Thesis delta

The FDA approval for the SIMLANDI process improvement is a modest positive, indicating that Alvotech is making progress on manufacturing efficiency and possibly regulatory compliance. However, it does not address the central risk of AVT05 CRL and the single-site operational fragility that underpins the WAIT rating. We maintain our WAIT stance but note that consistent regulatory engagement could de-risk the manufacturing narrative over time.